Shanghai Zhimeng Biopharma announces the successful completion of its phase 1b clinical trial on its novel HBV capsid inhibitor ZM-H1505R. It was a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy against HBV in treatment naive chronic hepatitis B patients, in which subjects were orally dosed at 50 mg, or 100 mg and 200 mg of ZM-H1505R or placebo once daily for 28 days, followed by a 28-day of following up visits. In October, all dosing regimen had been successfully completed and the last patient had finished all scheduled follow-up procedures on November 9. The results of this study will be presented in EASL’s 2022 International Liver Congress. Dr. Huanming Chen, CEO of Zhimeng Biopharma commented that we are pleased to see the successful completion of this 1b trial. It is a great achievement made by our team toward our goal to develop a functional cure therapy for HBV. It also reflects the high efficiency and standard by which we conduct clinical trials.
Reported on November 12, 2021